E.V. VOLYANYUK, A.I. SAFINA

City Children’s Hospital №1, 125a Dekabristov Str., Kazan, Russian Federation, 420034

Kazan State Medical Academy — Branch Campus of the RMACPE MOH Russia, 36 Butlerov Str., Kazan, Russian Federation, 420012

Volyanyuk E.V. ― Cand. Med. Sc., Head of the City Center for Catamnesis, Associate Professor of the Department of Pediatrics and Neonatology, tel. (843) 562-52-66, e-mail: volanuk@mail.ru

 The article analyzes the results of immunization of premature infants with bronchopulmonary dysplasia in the spring season of 2017 with the drug palivizumab in the Republic of Tatarstan. Small premature infants with bronchopulmonary dysplasia constitute a high-risk group of severe respiratory syncytial infection, which worsens the prognosis of the disease, and can lead to death. For immunoprophylaxis, monoclonal antibodies against the respiratory syncytial virus have been used in the recent years. The targeted funding of the program for the RSV infections prevention by рalivizumab in premature infants with bronchopulmonary dysplasia has shown not only a reduction in respiratory infections in general, but the elimination of the need for hospitalization of children who received three-time injections of the drug.

Key words: premature, bronchopulmonary dysplasia, palivizumab.

REFERENCES

1. Babak O.A., Vorontsova Yu.N., Geppe N.A. et al. Bronkholegochnaya displaziya. Metodicheskie rekomendatsii [Bronchopulmonary dysplasia. Methodical recommendations ]. Moscow: Izdatel’stvo GOU VPO RGMU Roszdrava, 2010. 47 p.
2. Simon A., Ammann R.A., Wilkesmann A. et al. Respiratory syncytial virus infection in 406 hospitalised premature infants: results from a prospective German multicentre database. Eur. J. Pediatr, 2007, 166, rr. 1273-1283.
3. Tatochenko V., Uchaikin V., Gorelov A. et al. Epidemiology of respiratory syncytial virus in children ≤2 years of age hospitalized with lower respiratory tract infections in the Russian Federation: a prospective, multicenter study. Clin. Epidemiol, 2010, 2, pp. 221-227.
4. Baranov A.A., Ivanov D.O., Alyamovskaya G.A. et al. Palivizumab: four seasons in Russia. Vestnik RAMN, 2014, pp. 7-8 (in Russ.).
5. Ovsyannikov D.Yu. Sistema okazaniya meditsinskoy pomoshchi detyam, stradayushchim bronkholegochnoy displazii. Rukovodstvo dlya praktikuyushchikh vrachey [The system of medical care for children suffering from bronchopulmonary dysplasia. A guide for practicing doctors]. Moscow, 2014. 15 p.
6. Volyanyuk E.V., Safina A.I. The effectiveness of the use of monoclonal antibodies to the respiratory syncytial virus in premature infants with bronchopulmonary dysplasia according to the follow-up data. Kazanskiy meditsinskiy zhurnal, 2015, no.4, pp. 21-25 (in Russ.).
7. Checchia P.A., Nalysnyk L., Fernandes A.W., et al. Mortality and and morbidity among infants at high risk for severe respiratory syncytial virus infection receving prophilaxis with palivizumab: A systematic literature review and meta-analysis. Pediatr. Crit. Care Med, 2011, no. 12 (5), rr. 580-8.
8. Namazova-Baranova L.T., Davydova I.V., Truti T.V. et al. Modern possibilities of immunoprophylaxis of severe course of respiratory syncytial virus infection in children with consequences of perinatal pathology. Pediatr. Farmakol., 2011, vol. 8, no. 4, pp. 92-100 (in Russ.).
9. Subramanian K.N., Weisman L.E., Rhodes T. et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr. Infect. Dis. J., 1998, vol. 17, pp. 110-115.
10. Vedenie detey s bronkholegochnoy displaziey [Management of children with bronchopulmonary dysplasia]. Federal’nye klinicheskie rekomendatsii. Soyuz pediatrov Rossii. Rossiyskaya assotsiatsiya spetsialistov perinatal’noy meditsiny. Moscow: Pediatr, 2014. 52 p.